
    
      This study is an open-label, non-randomized, uncontrolled, two-stage phase II study
      evaluating the efficacy and safety of ertumaxomab. Ertumaxomab will be administered three
      times at 7 day intervals by constant rate 3 hour intravenous (i.v.) infusions according to
      the following dose schedule: 10 µg (day 0); 100 µg (day 7 ± 1 day) and 100 µg (day 14 ± 1
      day) (flat doses).
    
  